Pristinamycin IIA ;
Antibiotic PA-114A ;
Antibiotic PA-114A1;
Factor M ;
Mikamycin A ;
NSC-244426 ;
NSC-87432 ;
Ostreogrycin A ;
PA-114A ;
RP-12536 ;
Staphylomycin M1 ;
Streptogramin A ;
Synergistin A1 ;
Vernamycin A ;
Virginiamycin M1 ;
8,9,14,15,24,25-Hexahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)(3R,4R,5E,10E,12E,14S)-3H-21,18-nitrolo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone ;
CAS # 21411-53-0 ; 270076-60-3 (Mixture of Pristinamycin IA & IIA) ;
C28H35N3O7 ;
MW: 525.59 ;
Impurity and intermediate of dalfopristin (ingredient for Synercid) ;
Pristinamycin is a streptogramin group antibiotic used primarily for the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is marketed in Europe by Sanofi-Aventis under the trade name "Pyostacine" which is a mixture of two components, ie, Pristinamycin IA and Pristinamycin IIA (30 : 70) with synergistic antibacterial action.
Pristinamycin IA may contain a minor impurity "Pristinamycin IB" (= "N-Desmethyl Pristinamycin IA").
Pristinamycin IIA may contain a minor impurity "Pristinamycin IIB" (= "Dihydro Pristinamycin IIA").